Cadila Healthcare Q3 profit surges 38.2 pct at Rs 389.6 cr

Pharma major Cadila Healthcare Ltd on Friday reported a growth of 38.2 per cent in its consolidated net profit after taxes (PAT) at Rs 389.6 crore for the third quarter ended December 31, 2015, on the back of robust sales in the US market. “The consolidated net profit of the drug firm stood at Rs 281.9 crore during the same period a year ago,” said Cadila Healthcare Ltd in a filing to the Bombay Stock Exchange on February 05, 2016. Further, its total income increased by 10.8 per cent at Rs 2,453.9 crore during Q3 2015-16, as compared to Rs 2,214.9 crore during the same period last year. During the quarter, the company’s business in the US posted sales of Rs 1072 crore registering a growth of 20 per cent. The company filed 20 ANDAs with the US Food and Drug Administration (USFDA) during the quarter, the company said in a statement. In the Indian formulations market, the company launched 12 new products, including line extensions, of which 1 product was the first to be launched in India, it added. Buoyed by earnings, shares of the company closed at Rs 326.80 apiece, up 4.74 per cent, from previous close on BSE